Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accuracy, acquire, acquired, affirm, al, allege, alleged, appraisal, arising, assert, Braschuk, Burnaska, challenging, competing, complaint, complying, confidentiality, counsel, Court, Del, Delaware, demanding, detrimental, discourage, District, employment, entry, fact, false, forbear, Franchi, improperly, injunction, Joe, Kaboom, Kapital, lawsuit, Mascara, Master, merge, merit, misleading, MSD, multiplied, notification, NRM, Opportunity, Pharmaceutical, plaintiff, preliminary, premium, prohibition, promulgated, proxy, publicly, purported, purpose, pursuit, recommend, recommendation, refrain, regular, signature, soliciting, Southern, spent, styled, survive, surviving, tender, vi, vigorously, violated, waived, withdraw, withhold, York
Removed:
comparable
Financial report summary
?Competition
Abeona Therapeutics • RenovaCare • Plus Therapeutics • Quoin Pharmaceuticals • Krystal BiotechRisks
- Failure to complete the Merger could negatively impact the price of our common stock, as well as our future business and financial results.
- The Merger Agreement limits our ability to pursue alternatives to the Merger and may discourage other companies from trying to acquire us for greater consideration than what CCP Holdings has agreed to pay.
- The CCP License Agreement is important to our business. If we or CCP fail to adequately perform under the CCP License Agreement, or if we or CCP terminate the CCP License Agreement, the development and commercialization of FCX-007 would be delayed or terminated and our business would be adversely affected.
Management Discussion
- Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
- We are a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue. We are utilizing our proprietary autologous fibroblast technology to develop personalized biologics that target the underlying cause of disease. Fibroblasts are the most common cell in skin and connective tissue and are responsible for synthesizing extracellular matrix proteins, including collagen and other growth factors, that provide structure and support. Because fibroblasts naturally reside in the localized environment of the skin and connective tissue, they represent an ideal delivery vehicle for proteins targeted to these areas. We target the underlying cause of disease by using fibroblast cells from a patient’s skin and genetically modifying them to create localized therapies that are compatible with the unique biology of the patient (i.e., which are autologous).
- Our pipeline of localized gene therapy candidates include FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a life-threatening genetic disorder diagnosed in infancy with no cure or treatment approved by the U.S. Food and Drug Administration (FDA). We are also developing FCX-013 for the treatment of moderate to severe localized scleroderma. Currently, all of our research and development operations and focus are on gaining regulatory approvals to commercialize our gene therapy candidates in the United States; however, we may seek to expand into international markets in the future.